Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProApix: Apixaban Pharmacodynamics in Multiple Myeloma vs Total Knee Replacement
NCT06474182Recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apixaban in venous thromboembolism (VTE), sponsored by CHU Saint-Etienne. Primary endpoint: Endogenous Thrombin potential at 2 hours. Started Sep 2025; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06474182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474182.